{"id":105498,"date":"2021-01-26T10:56:34","date_gmt":"2021-01-26T10:56:34","guid":{"rendered":"https:\/\/fin2me.com\/?p=105498"},"modified":"2021-01-26T10:56:34","modified_gmt":"2021-01-26T10:56:34","slug":"novartis-ceo-renews-commitment-to-sandoz-generics-unit","status":"publish","type":"post","link":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/","title":{"rendered":"Novartis CEO renews commitment to Sandoz generics unit"},"content":{"rendered":"
FILE PHOTO: Novartis CEO Vas Narasimhan addresses the Swiss drugmaker’s annual news conference in Basel, Switzerland, January 30, 2019. REUTERS\/Arnd Wiegmann\/File Photo<\/figcaption>

ZURICH (Reuters) – Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pandemic.<\/p>\n

\u201cWe remain committed to the Sandoz business,\u201d Narasimhan said during the company\u2019s annual results news conference, when asked about the Swiss company\u2019s plans for the generics unit that over the years has been subject of disposal or spin-off speculation.<\/p>\n

Novartis\u2019s fourth-quarter results on Tuesday missed analyst forecasts. Narasimhan also announced a revamp of his digital operations, including the exit of Chief Digital Officer Bertrand Bodson.<\/p>\n

Source: Read Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

FILE PHOTO: Novartis CEO Vas Narasimhan addresses the Swiss drugmaker’s annual news conference in Basel, Switzerland, January 30, 2019. REUTERS\/Arnd Wiegmann\/File PhotoZURICH (Reuters) – Novartis […]<\/p>\n","protected":false},"author":3,"featured_media":105497,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"yoast_head":"\nNovartis CEO renews commitment to Sandoz generics unit - Fin2me<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis CEO renews commitment to Sandoz generics unit - Fin2me\" \/>\n<meta property=\"og:description\" content=\"FILE PHOTO: Novartis CEO Vas Narasimhan addresses the Swiss drugmaker’s annual news conference in Basel, Switzerland, January 30, 2019. REUTERS\/Arnd Wiegmann\/File PhotoZURICH (Reuters) – Novartis [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/\" \/>\n<meta property=\"og:site_name\" content=\"Fin2me\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-26T10:56:34+00:00\" \/>\n<meta name=\"author\" content=\"Mark\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/01\/cnewsfotor2-10.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/\",\"url\":\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/\",\"name\":\"Novartis CEO renews commitment to Sandoz generics unit - Fin2me\",\"isPartOf\":{\"@id\":\"https:\/\/fin2me.com\/#website\"},\"datePublished\":\"2021-01-26T10:56:34+00:00\",\"dateModified\":\"2021-01-26T10:56:34+00:00\",\"author\":{\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\"},\"breadcrumb\":{\"@id\":\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fin2me.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Business\",\"item\":\"https:\/\/fin2me.com\/category\/business\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Novartis CEO renews commitment to Sandoz generics unit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fin2me.com\/#website\",\"url\":\"https:\/\/fin2me.com\/\",\"name\":\"Fin2me\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fin2me.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\",\"name\":\"Mark\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"caption\":\"Mark\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novartis CEO renews commitment to Sandoz generics unit - Fin2me","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/","og_locale":"en_US","og_type":"article","og_title":"Novartis CEO renews commitment to Sandoz generics unit - Fin2me","og_description":"FILE PHOTO: Novartis CEO Vas Narasimhan addresses the Swiss drugmaker’s annual news conference in Basel, Switzerland, January 30, 2019. REUTERS\/Arnd Wiegmann\/File PhotoZURICH (Reuters) – Novartis [...]","og_url":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/","og_site_name":"Fin2me","article_published_time":"2021-01-26T10:56:34+00:00","author":"Mark","twitter_card":"summary_large_image","twitter_image":"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/01\/cnewsfotor2-10.jpg","twitter_misc":{"Written by":"Mark","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/","url":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/","name":"Novartis CEO renews commitment to Sandoz generics unit - Fin2me","isPartOf":{"@id":"https:\/\/fin2me.com\/#website"},"datePublished":"2021-01-26T10:56:34+00:00","dateModified":"2021-01-26T10:56:34+00:00","author":{"@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a"},"breadcrumb":{"@id":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fin2me.com\/business\/novartis-ceo-renews-commitment-to-sandoz-generics-unit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fin2me.com\/"},{"@type":"ListItem","position":2,"name":"Business","item":"https:\/\/fin2me.com\/category\/business\/"},{"@type":"ListItem","position":3,"name":"Novartis CEO renews commitment to Sandoz generics unit"}]},{"@type":"WebSite","@id":"https:\/\/fin2me.com\/#website","url":"https:\/\/fin2me.com\/","name":"Fin2me","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fin2me.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a","name":"Mark","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fin2me.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","caption":"Mark"}}]}},"_links":{"self":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/105498"}],"collection":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/comments?post=105498"}],"version-history":[{"count":0,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/105498\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media\/105497"}],"wp:attachment":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media?parent=105498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/categories?post=105498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/tags?post=105498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}